ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Grafico Intraday: NASDAQ Biotechnology Index
Grafico Storico: NASDAQ Biotechnology Index
Grafico Intraday: Nasdaq Health Care Index
Grafico Storico: Nasdaq Health Care Index
Biotecnologie: scommessa o investimento?
La richiesta di attrezzature mediche, di nuovi farmaci, di terapie innovative per combattere le malattie legate all’invecchiamento aumenta senza sosta.
Se affrontato con cognizione e professionalità, e soprattutto con una visione di medio-lungo termine, l’investimento in biotecnologia permette senza dubbio sonni tranquilli: le sottolineo come nel 1989 il fatturato della biotecnologia era US$ 2,7 miliardi. Nel 2008 le case biotech hanno incassato US$ 90 miliardi. Questi numeri, uniti al fatto che attualmente vi sono più di 800 i farmaci biotech nelle varie fasi di sviluppo per malattie come cancro, alzheimer, malattie cardiovascolari, diabete, sclerosi multipla ed artrite dovrebbero far capire agli investitori come i titoli biotech rappresentino un’opportunità d’investimento paragonabile agli investimenti fatti nelle case farmaceutiche tradizionali nei anni ’60-’80. Un investimento sicuro fondato su solide basi.
estratto di un articolo comparso su Soldionline al link
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Mentor Capital Cancer Index Start Oversubscribed
Monday, February 01, 2010 12:11 PM
(Source: Business Wire)trackingMentor Capital, Inc.'s (Pink Sheets:MNTR) first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
By overweighting the investment of this $125 Million into the most promising Index companies, Mentor Capital seeks to exceed the return of the equally weighted CI Index. The Cancer Immunotherapy Index has grown at an annualized 90% rate since its original creation by Mentor Capital twenty-nine weeks ago.
The current ten CI Index companies that Mentor Capital has invested into are: Dendreon (NASDAQ:DNDN), Immunocellular Therapeutics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company. In addition to actively managing its investment into these companies, Mentor Capital looks to occasionally add emerging companies to the Index as they reach an adequate size or shift their immunotherapy emphasis from infectious disease to the cancer fight.
Level II trading charts, financial and other information on Mentor Capital, plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
A service of YellowBrix, Inc.
2 di 4211-04/2/2010 23:400
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Certo che comunque non sarà tutto così semplice...
3 di 4211-04/2/2010 23:450
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
PROVO A RIPORTARE LA DISCUSSIONE GIA' AVVIATA IN ALTRO 3D PER PROSEGUIRE IN QUESTO
INTANTO SE PROVIAMO A FARE UN CONFRONTO STORICO DI GRAFICI GIA' ABBIAMO UNA PRIMA INDICAZIONE POSITIVA.
4 di 4211-05/2/2010 00:030
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Il settore sta attirando continuamente un sacco di capitali. Basti pensare agli innumerevoli collocamenti che queste aziende fanno per reperire i capitali destnati alla ricerca e allo sviluppo dei loro studi.
Non credo siano i soldi dei piccoli risparmiatori ma bensì capitali di grossi investitori e fondi che probabilmente si aspettano ritorni in futuro.
In Italia ad esempio Fininvest ha incrementato la sua quota in MolMed, non credo che lo abbiano fatto comeparcheggio della liquidità.
Comunque prime segnalazioni da seguire e valutare (tralasciando le azioni che sono già ben più alte):
Antigenics (NASDAQ:AGEN)
Sunesis Pharmaceuticals, Inc. ( NASDAQ:SNSS)
Generex Biotechnology (NASDAQ:GNBT)
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX)
Cyclacel Pharmaceuticals Inc. ( NASDAQ:CYCC)
5 di 4211-05/2/2010 14:310
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
in Italia Molmed
6 di 4211-05/2/2010 15:370
axel06
N° messaggi: 1866 -
Iscritto da: 13/2/2008
Ottimo Inizio Ciappola.
7 di 4211-05/2/2010 15:550
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
per proseguire....
Nasdaq Composite Vs Nasdaq Biotech
8 di 4211-05/2/2010 21:520
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
altre segnalazioni daseguire, peccato che non posso operare su otc
Somaxon Pharmaceuticals NASDAQ:SOMX (oggi +10%, interessante l'avevo già inserito nella mia watch list. da seguire e approfondire)
Cancer Therapeutics USBB:CTHP (OTC BB) (non so proprio dove scambia, comunque sarebbe da approfondire)
Hemispherx Biopharma, AMEX:HEB
Cel-Sci-Sci Corp AMEX:CVM
chi ha altri titoli da segnalare e da approfondire è benvenuto
9 di 4211-05/2/2010 22:050
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Nasdaq:TTHI Transition Therapeutics Inc.
10 di 4211-Modificato il 05/2/2010 22:140
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
evento importante, lunedì
12th Annual BIO CEO & Investor Conference on February 8th, 2010 at 10:00 am local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf=Astoria, New York.
about BIO CEO & Investor Conference
Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit www.ceo.bio.org.
11 di 4211-05/2/2010 22:110
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Novavax, Inc. NASDAQ:NVAX
12 di 4211-05/2/2010 22:340
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
può essere utile (anche perchè credo che il calendario della FDA sia a pagamanento)
Biotech Calendar: Upcoming FDA Dates
By Adam Feuerstein 12/15/09 - 05:05 AM EST
BOSTON, Mass. (TheStreet) --To get ready for 2010, I've put together a new calendar of expected U.S. Food and Drug Administration approval decisions.
These can be make-or-break events for drug and biotech companies, so naturally, FDA decisions often move stocks significantly.
The following calendar covers most of the expected drug approval decisions by the FDA through the end of June 2010. I expanded the calendar to include drug application filings and other important regulatory events like advisory committee meetings.
I put the calendar together using company reports and the BioMedTracker service from Sagient Research -- a handy, subscription-based tool for keeping track of biotech and drug catalysts.
Chelsea Therapeutics(CHTP Quote)
Drug/indication: Droxidopa for neurogenic orthostatic hypotension
Outcome of FDA meeting to discuss changing primary endpoint of phase III study: December 2009.
Cephalon(CEPH Quote)
Drug/indication: Nuvigil for jet lag disorder
FDA approval decision date: Dec. 29
Arena Pharmaceuticals(ARNA Quote)
Drug/indication: lorcaserin for obesity
Filing for FDA approval: December 2009
Auxilium Pharmaceuticals(AUXL Quote)
Drug/indication: Xiaflex for Dupuytren's contracture
FDA approval decision date: December 2009
Biodel(BIOD Quote)
Drug/indication: Viaject for diabetes
Filing for FDA approval: December 2009
Novartis(NVS Quote)
Drug/indication: fingolomid for multiple sclerosis
Filing for FDA approval: December 2009
Novo Nordisk(NVO Quote)
Drug/indication: Victoza for diabetes
FDA approval decision date: December 2009
Shire Pharmaceuticals(SHPGY Quote)
Drug/indication: Replagal for Fabry's disease
Filing for FDA approval: December 2009
Vivus(VVUS Quote)
Drug/indication: Qnexa for obesity
Filing for FDA approval: December 2009
Mannkind(MNKD Quote)
Drug/indication: Afresa for diabetes
FDA approval decision date: Jan. 16, 2010
Acorda Therapeutics(ACOR Quote)
Drug/indication: Amaya for multiple sclerosis
FDA approval decision date: Jan. 22, 2010
Spectrum Pharmaceuticals(SPPI Quote)
Drug/indication: Fusilev for colon cancer
Outcome of meeting with FDA to discuss complete response letter: January 2010
Labopharm(DDSS Quote)
Drug/indication: Trazodone Contramid for depression
FDA approval decision date: Feb. 11, 2010
Cadence Pharmaceuticals(CADX Quote)
Drug/indication: acetavance for pain
FDA approval decision date: Feb. 12, 2010
Gilead Sciences(GILD Quote)
Drug/indication: Cayston for cystic fibrosis
FDA approval decision date: Feb. 13, 2010
Salix Pharmaceuticals(SLXP Quote)
Drug/indication: Xifaxan for hepatic encephalopathy
FDA advisory committee meeting: February 2010
FDA approval decision date: March 24, 2010
Shire Pharmaceuticals(SHPGY Quote)
Drug/indication: velaglucerase for Gaucher's disease
FDA approval decision date: Feb. 28, 2010
Amylin Pharmaceuticals(AMLN Quote)
Drug/indication: Exenatide LAR for diabetes
FDA approval decision date: March 5, 2010
Clinical Data(CLDA Quote)
Drug/indication: vilazodone for depression
Filing for FDA approval: First quarter 2010
Somaxon Pharmaceuticals(SOMX Quote)
Drug/indication: Silenor for insomnia
Outcome of FDA meeting to discuss complete response letter: First quarter 2010
Cell Therapeutics(CTIC Quote)
Drug/indication: pixantrone for non-Hodgkin's lymphoma
FDA approval decision date: April 23, 2010
Eli Lilly(LLY Quote)
Drug/indication: Erbitux for first-line non-small cell lung cancer
Filing for FDA approval: First quarter 2010
Dendreon(DNDN Quote)
Drug/indication: Provenge for prostate cancer
FDA approval decision date: May 1, 2010
Avanir Pharmaceuticals(AVNR Quote)
Drug/indication: Zenvia for pseudobulbar effect
Filing for FDA approval: Second quarter 2010
Alkermes(ALKS Quote)
Drug/indication: Vivitrol for opioid addiction
Filing for FDA approval: First half 2010
InterMune(ITMN Quote)
Drug/indication: pirfenidone for idiopathic pulmonary fibrosis
FDA advisory committee meeting: First half 2010
FDA approval decision date: Second half 2010
Human Genome Sciences(HGSI Quote)
Drug/indication: Benlysta for lupus
Filing for FDA approval: First half 2010
Orexigen Therapeutics(OREX Quote)
Drug/indication: Contrave for obesity
Filing for FDA approval: First half 2010
-- Reported by Adam Feuerstein in Boston
13 di 4211-Modificato il 05/2/2010 23:050
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Cytomedix, Inc. (NYSE AMEX:GTF)
DA response on Autologel Sytem Expected Soon (AMEX:GTF)
By John McCalister on 02/04/2010 – 9:37 am PSTLeave a Comment
FDA response on Autologel Sytem Expected Soon (AMEX:GTF)
On August 7, 2009, Cytomedix, Inc. (NYSE AMEX:GTF) announced that it has submitted to, the United Sates of America’s toughest regulator, the Food and Drug Administration (FDA) a 510(K) for its AutoloGel™ Platelet Separation System. The 510(K) submission was made to obtain pre market approval from the FDA. We anticipate they will get a response from the FDA after 6 months, i.e. on or around February 7, 2010. However, the FDA may not give its decision on this date and there is no way to find out when it will, since the FDA is not bound by law to notify about decision dates for any submission, such as 510(K), related to medical devices.
So, what exactly is a 510(K) submission? It is an application submitted to the Centre for Devices and Radiological Health (CDRH), an organ of the FDA), by companies who want to commercialize a line of medical devices that they have developed. Almost all medical devices need the submission and approval of the 510(K) application. The 510(K) submission basically allows the company to prove to the Food & Drug Administration that the medical device is both safe and effective. On the other hand, the 510(K) submission may also show how the medical device is same as a predicate device, that is, a device that is already legally available in the market and does not require submitting a pre market approval to the FDA.
The company has carried out clinical trials on Autologel™ system. The trials found out that the PRP (platelet-rich plasma) that has been achieved by the medical device must be mixed with bones (autograft and allograft) before the Autologel™ system is applied on the orthopedic site.
Martin P. Rosendale, who is the Chief Executive Officer of Cytomedix, Inc., said:
“This filing of our Platelet Separation System for orthopedic applications provides further enhancements to our existing AutoloGel™ System and streamlines the process to produce the gel, thereby making the clinical process more efficient. Upon clearance, we will look forward to bringing these advances to our growing customer base, with opportunities for expanded indications of use.”
14 di 4211-06/2/2010 14:570
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Mentor Capital Announces Plan for New 2010 Actively Managed Cancer Immunotherapy Index and 45 Day Call on C Warrants for CI Index Seed Funding
Monday, December 14, 2009 4:06 PM Email Article Bookmark: TwitterDeliciousDiggYahoo BuzzFacebookStumbleuponLinked InMy SpaceNewsvine Font Size Print Article
(Source: Business Wire)Mentor Capital, Inc.'s (Pink Sheets:MNTR) proprietary Cancer Immunotherapy Index has appreciated at a 100% annualized rate since its creation by Mentor Capital, July 10, 2009. In response to the resulting investor interest, Mentor Capital plans to initiate an actively managed Cancer Immunotherapy Index fund in January 2010. A significant majority of Mentor Capital cash proceeds that spring from its $140 million in freely tradable warrants are targeted to be invested through the fund.
Investment across the Cancer Immunotherapy Index will broaden Mentor Capital's already significant immunotherapy investment interest in CI Index member Quantum Immunologics, Inc., a private company in FDA authorized breast cancer trials. Other Cancer Immunotherapy Index companies are: Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), ImmunoCellular Theraputics (OTCBB:IMUC), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly owned immunotherapeutic subsidiary, Antigen Express. As other companies are brought into the CI Index, Mentor Capital will take an investment position in them with specific weighting based on the evaluation of their medical promise.
$1.2 million in initial seed funding for the CI Index will be provided approximately one-third each by Mentor Capital management, WellCap Partners who will administer the fund under Mentor Capital direction, and Mentor Capital warrant holders. To allow for the Mentor Capital warrant holder funding, their Mentor Capital Series C warrants are set to $0.65 and called by this notice, subject to redemption on February 1, 2010.
In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body's own immune system is triggered to attack cancer cells. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 billion. The current combined market cap of the index component companies is $3.4 billion.
Regular detail updates of the Cancer Immunotherapy Index and additional company information may be reviewed at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
interessante articolo su GNBT Generex Biotechnology http://seekingalpha.com/article/183604-will-generex-biotech-be-next-to-join-the-winner-s-circle
16 di 4211-09/2/2010 16:470
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
ho cominciato a costruirmi un portafoglio di biotech inserendo Generex e Cytomedix con Sunesiss.
Penso che se si crede nel settore bisogna diversificare nei vari titoli che possono avere un buon potenziale in quanto il settore è il più speculativo in assoluto, difficile da gestire e con possibili sorprese positive e anche assolutamente negative e imprevedibili.
Bisogna conoscere le fasi di studio, le dimensioni del possibile mercato di sbocco, lo stato di avanzamento delle assegnazioni dei diritti di sviluppo, fabbricazione e vendita dei vari farmaci.
Per meglio tenere sott'okkio il ptf vi consiglio un account su google finance, inserite i titoli che vi interessano nel portafoglio e automaticamente avrete tutte le news dei titoli in osservazione.
17 di 4211-Modificato il 09/2/2010 17:060
skizzomo
N° messaggi: 371 -
Iscritto da: 22/9/2009
Ciappola mi scrivi cortesemente il codice di Cytomedix.
Grazie mille
Trovata grazie ugualmente.
A titolo informativo quante ne hai prese di Cyto e Generex?
Io di Snss ABBASTANZA.
18 di 4211-09/2/2010 23:570
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
ho sbagliato puntando tutto su uno solo (snss), come prima mossa. circa 7.000 usd. poi ho inserito gli altri due togliendo (stop loss graduale) da snss che per ora sta deludendo. dei due per ora circa 1.000 usd ciascuno.
ne inserirò probabilmente un altro, stesso importo ma l'investimento iniziale rimarrà quello originario (decurtato della minus già in progresso....)
Settore troppo speculativo e imprevedibile. Ancora da studiare
19 di 4211-10/2/2010 14:380
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
AMEX:RNN
altra società da seguire, c'è un interessante e ampio articolo su google finance
20 di 4211-10/2/2010 17:210
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
Informazioni sulla discussione
Torna alla Lista
Aggiorna Lista
Mentor Capital Cancer Index Start Oversubscribed
Monday, February 01, 2010 12:11 PM
(Source: Business Wire)trackingMentor Capital, Inc.'s (Pink Sheets:MNTR) first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
By overweighting the investment of this $125 Million into the most promising Index companies, Mentor Capital seeks to exceed the return of the equally weighted CI Index. The Cancer Immunotherapy Index has grown at an annualized 90% rate since its original creation by Mentor Capital twenty-nine weeks ago.
The current ten CI Index companies that Mentor Capital has invested into are: Dendreon (NASDAQ:DNDN), Immunocellular Therapeutics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company. In addition to actively managing its investment into these companies, Mentor Capital looks to occasionally add emerging companies to the Index as they reach an adequate size or shift their immunotherapy emphasis from infectious disease to the cancer fight.
Level II trading charts, financial and other information on Mentor Capital, plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
A service of YellowBrix, Inc.